Key Takeaways:
Clarivate Plc agreed to sell its Life Sciences & Healthcare segment to Altaris LLC for $600 million, shedding a lower-margin business to refocus on AI-powered subscription intelligence for academic and intellectual property clients.
"The complementary nature of A&G's and IP's businesses will enhance efficiency, sharpen execution, strengthen innovation and grow customer reach," said Matti Shem Tov, chief executive officer of Clarivate, in a statement.
Under the terms, Clarivate will receive $500 million in cash at closing, $25 million in deferred cash tied to a transition services agreement and a $75 million seller note. The company plans to use the proceeds to reduce its $4.34 billion debt load. The transaction is expected to close by year-end, subject to regulatory approvals.
The divestiture marks a strategic pivot for the London-based company, which will now operate as a subscription-first provider of intelligence solutions, workflow software and tech-enabled services across its Academia & Government and Intellectual Property segments. Both segments share content assets and technology platforms, and the company expects the sharper focus to improve revenue mix, expand adjusted EBITDA margins and lower capital intensity.
Deal Structure and Financial Impact
Clarivate reaffirmed its full-year 2026 outlook, which includes the LS&H segment through the first half. For the full year, the company projects revenue of $1.94 billion to $2.04 billion excluding discontinued operations, and $2.3 billion to $2.42 billion including them. Adjusted EBITDA is forecast at $980 million to $1.04 billion, representing a margin of 42 percent to 43.5 percent, while adjusted diluted earnings per share are seen at $0.70 to $0.80.
The company expects to record a non-cash goodwill impairment of $225 million to $250 million on the segment based on the sale price, which will not affect its financial outlook metrics.
Morgan Stanley & Co. served as financial adviser, with Davis Polk & Wardwell and Hogan Lovells providing legal counsel.
The sale simplifies Clarivate's corporate structure at a time when investors have pressed for sharper focus and debt reduction. The company's shares rose 16.7 percent to $2.59 on the announcement, reflecting market approval of the strategic shift. With the LS&H segment classified as discontinued operations starting in the third quarter, Clarivate's remaining business will generate roughly $2 billion in annual revenue with higher subscription content mix and lower capital intensity.
The deal also positions Altaris, a healthcare-focused investment firm, to build on the LS&H segment's drug and device lifecycle analytics platform with continued investment, according to Henry Levy, president of the unit.
This article is for informational purposes only and does not constitute investment advice.
